戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 etylcholinesterase) or nonexisting (synaptic acetylcholinesterase).
2 sly validated for imaging cerebral levels of acetylcholinesterase.
3 resulted in a comparable enhanced release of acetylcholinesterase.
4 he essential oil was the most active against acetylcholinesterase.
5 , octopamine synapses, and the inhibition of acetylcholinesterase.
6 tor neuron function and stability, including acetylcholinesterase.
7 components of decay, even in the presence of acetylcholinesterase.
8 re homologous to the dimerization helices of acetylcholinesterase.
9 via a mechanism that depends on both p53 and acetylcholinesterase.
10 f cholinergic transmission via inhibition of acetylcholinesterase.
11 s, in addition to inhibiting the activity of acetylcholinesterase.
12                                              Acetylcholinesterase 1 (AmAChE1) of the honey bee, Apis
13 potential label-free detection system, using acetylcholinesterase (acetylcholine acetylhydrolase; EC
14 icity assessment, including determination of acetylcholinesterase (AChE) activity, genotoxicity and o
15 s acid (HOCl) assays, and their potential as acetylcholinesterase (AChE) and butyrylcholinesterase (B
16 or their potential inhibitory effect on both acetylcholinesterase (AChE) and butyrylcholinesterase (B
17 en advantage of the distinct localization of acetylcholinesterase (AChE) and butyrylcholinesterase (B
18  tinus L. was investigated via inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (B
19 pounds with nanomolar potencies toward human acetylcholinesterase (AChE) and butyrylcholinesterase (B
20                         The cholinesterases, acetylcholinesterase (AChE) and butyrylcholinesterase, a
21 based on poly(o-phenylenediamine) (PoPD) and acetylcholinesterase (AChE) and choline oxidase (ChO) en
22  by co-immobilizing covalently, a mixture of acetylcholinesterase (AChE) and choline oxidase (ChO) on
23 tion is constructed by immobilizing enzymes, acetylcholinesterase (AChE) and choline oxidase (ChO), o
24 wed by chemical cross-linking of the enzymes acetylcholinesterase (AChE) and choline oxidase (ChO).
25                 We show that miR-608 targets acetylcholinesterase (AChE) and demonstrate weakened miR
26 ouble stranded RNA (dsRNA) homologous to the acetylcholinesterase (AChE) and ecdysone receptor (EcR)
27  sites of bovine carbonic anhydrase (BCA) or acetylcholinesterase (AChE) and inhibit their catalytic
28 atform for simple and sensitive detection of acetylcholinesterase (AChE) and its inhibitor using a ca
29 erapeutics for AD through dual inhibition of acetylcholinesterase (AChE) and microRNA-15b biogenesis.
30  targets for Alzheimer's disease (AD), i.e., acetylcholinesterase (AChE) and monoamine oxidase B (MAO
31            The chemistry described here uses acetylcholinesterase (AChE) and produces an unambiguous
32  this work we investigated the expression of acetylcholinesterase (AChE) and the density of myelinate
33 he molecular interactions between the enzyme acetylcholinesterase (AChE) and two compound classes con
34                    The catalytic subunits of acetylcholinesterase (AChE) are anchored in the basal la
35         Choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) are the decisive enzymatic a
36 isplays the identical binding mechanism with acetylcholinesterase (AChE) as its more potent counterpa
37 pectrometric detection and a high throughput acetylcholinesterase (AChE) assay was developed.
38 and effect-directed analysis (EDA) using the acetylcholinesterase (AChE) bioassay and metabolomics.
39                                              Acetylcholinesterase (AChE) biosensor was developed thro
40                  A sensitive electrochemical acetylcholinesterase (AChE) biosensor was successfully d
41                               OPs inactivate acetylcholinesterase (AChE) by covalently modifying its
42                      Ligand binding sites on acetylcholinesterase (AChE) comprise an active center, a
43                                              Acetylcholinesterase (AChE) converts ACh to choline, whi
44             Towards this, a highly sensitive acetylcholinesterase (AChE) cyclic voltammetric biosenso
45 fect of temperature on the kinetics of brain Acetylcholinesterase (AChE) during adaptation to subleth
46 de organophosphate insecticides that inhibit acetylcholinesterase (AChE) enzyme activity in the salmo
47 l Organic Framework (MOF-Basolite Z1200) and Acetylcholinesterase (AChE) enzyme served as an excellen
48 e (PHA), which mimics the performance of the acetylcholinesterase (AChE) enzyme.
49  biosensor that employs genetically modified acetylcholinesterase (AChE) enzymes B394, B4 and wild ty
50 activity of angiotensin-converting (ACE) and acetylcholinesterase (AChE) enzymes.
51                     Like its homologs in the acetylcholinesterase (AChE) family, ChEL possesses two c
52                    A series of inhibitors of acetylcholinesterase (AChE) have been screened by back-s
53 olive oil, based on a genetically-engineered acetylcholinesterase (AChE) immobilized in a azide-unit
54 aking advantage of the crystal structures of acetylcholinesterase (AChE) in complex with galantamine
55 y binds to aromatic residues of OP-inhibited acetylcholinesterase (AChE) in orientations that are non
56 showed improved inhibitory properties toward acetylcholinesterase (AChE) in relation to tacrine.
57                         The synaptic form of acetylcholinesterase (AChE) in skeletal muscle ColQ-AChE
58                            The expression of acetylcholinesterase (AChE) in skeletal muscle is regula
59 ber of studies detailing the distribution of acetylcholinesterase (AChE) in the hippocampal formation
60 xicants is due to irreversible inhibition of acetylcholinesterase (AChE) in the nervous system.
61 reased during the initial period and that of acetylcholinesterase (AChE) increased during a later tim
62 ldoximes are used as antidotes to reactivate acetylcholinesterase (AChE) inhibited by organophosphoru
63 al-missions of Abeta-targeting clearance and acetylcholinesterase (AChE) inhibition in AD therapy.
64 valuated using a previously established AOP, acetylcholinesterase (AChE) inhibition.
65  herein that RS67333 is also a submicromolar acetylcholinesterase (AChE) inhibitor and therefore, cou
66 , that bis(heptyl)-cognitin, a novel dimeric acetylcholinesterase (AChE) inhibitor derived from tacri
67                                              Acetylcholinesterase (AChE) inhibitors are commonly used
68                                              Acetylcholinesterase (AChE) inhibitors are potentially l
69 ganophosphorus (OP) and methylcarbamate (MC) acetylcholinesterase (AChE) inhibitors.
70 ich sources of phenolic compounds, exhibited acetylcholinesterase (AChE) inhibitory activity and also
71 anti-cancer, anti-viral, anti-parasitic, and acetylcholinesterase (AChE) inhibitory activity, were de
72 is-furans and one dihydropyran isomer showed acetylcholinesterase (AChE) inhibitory activity.
73   In vitro, 15 compounds displayed excellent acetylcholinesterase (AChE) inhibitory potencies and int
74                                        Human acetylcholinesterase (AChE) is a significant target for
75                                              Acetylcholinesterase (AChE) is crucial for degrading ace
76 ransmitters in the human body, by the enzyme acetylcholinesterase (AChE) is fundamental for the termi
77                                              Acetylcholinesterase (AChE) is highly expressed at sites
78               In the central nervous system, acetylcholinesterase (AChE) is present in a tetrameric f
79                             By utilizing the acetylcholinesterase (AChE) mediated hydrolysis of acety
80       The vast majority of newly synthesized acetylcholinesterase (AChE) molecules do not assemble in
81 ) and anthocyanins (r = 0.312 and 0.301) for acetylcholinesterase (AChE) or butylcholinoesterase (BuC
82  sensing strategy involves reacting ACh with acetylcholinesterase (AChE) to form choline that is in t
83  frozen, serially sectioned, and stained for acetylcholinesterase (AChE) to identify the NMJs.
84 rseradish peroxidase and surface coated with acetylcholinesterase (AChE) were attached to gold screen
85 -oxime reactivation rates for OP-inactivated acetylcholinesterase (AChE) were lower compared to 2-PAM
86 can be induced in humans through blockade of acetylcholinesterase (AChE) whereas antidepressant-like
87  to investigate inhibition of human BChE and acetylcholinesterase (AChE) with metaproterenol, isoprot
88 tivators of chemical warfare agent inhibited acetylcholinesterase (AChE) with promising in vitro pote
89 ing bovine serum albumin and conjugated with acetylcholinesterase (AChE), an enzyme specific for acet
90 g the N-methyl-d-aspartate receptor (NMDAR), acetylcholinesterase (AChE), and monoamine oxidase B (MA
91 his work, the selected target was the enzyme acetylcholinesterase (AChE), and the AChE-ICERs produced
92 It is selectively reduced by the addition of acetylcholinesterase (AChE), and thus appears to involve
93 ucleus, distinct in cytochrome oxidase (CO), acetylcholinesterase (AChE), and vesicular glutamate tra
94 Inhibitory activity of the conjugates toward acetylcholinesterase (AChE), butyrylcholinesterase (BChE
95 ontain several cholinergic factors including acetylcholinesterase (AChE), choline acetyltransferase (
96 onjugates (MB-gCs) against human erythrocyte acetylcholinesterase (AChE), equine serum butyrylcholine
97 immunocytochemical stains were performed for acetylcholinesterase (AChE), nicotinamide adenine dinucl
98 whether APP is involved in the regulation of acetylcholinesterase (AChE), which is a key protein of t
99 variable and insensitive to perturbations of acetylcholinesterase (AChE), while slow non-alpha7 recep
100 iated with an abnormal sprouting response of acetylcholinesterase (AChE)-positive fibers, a phenotype
101 tly binding to the active site of the enzyme acetylcholinesterase (AChE).
102 ow antioxidant properties, and inhibit human acetylcholinesterase (AChE).
103 sly block the active and peripheral sites of acetylcholinesterase (AChE).
104 enisn-converting enzyme (ACE) and the enzyme acetylcholinesterase (AChE).
105  as the result of irreversible inhibition of acetylcholinesterase (AChE).
106            Among its other biological roles, acetylcholinesterase (AChE, EC 3.1.1.7), encoded by two
107           We reported previously that insect acetylcholinesterases (AChEs) could be selectively and i
108 f synaptic acetylcholine (ACh) by tetrameric acetylcholinesterase (AChEt).
109 ge (thiobarbituric acid reactive substances, acetylcholinesterase, acid phosphatase), no significant
110 lcholine levels resulting from inhibition of acetylcholinesterase act on such receptors.
111  P = 0.13), but not significant for cortical acetylcholinesterase activity (F = 0.3, P = 0.75).
112 ed a significant regressor effect for limbic acetylcholinesterase activity (F = 10.1, P < 0.0001), bo
113 roteins, reactive oxygen species, and higher acetylcholinesterase activity are also strongly associat
114 c (hippocampal and amygdala) and neocortical acetylcholinesterase activity as well as striatal monoam
115 midinopropane) dihydrochloride and inhibited acetylcholinesterase activity by 85%.
116  and encapsulated lutein was able to inhibit acetylcholinesterase activity even in an aqueous medium.
117             In addition, Smu. 1393c protects acetylcholinesterase activity from being inhibited by tw
118 ation test scores correlated positively with acetylcholinesterase activity in the hippocampal formati
119 O-glycosyl flavonoids on the antioxidant and acetylcholinesterase activity of these juices has been e
120 ecreased the levels of SE-bound CD63/CD9 and acetylcholinesterase activity respectively.
121                                     The anti-acetylcholinesterase activity was higher in butanol extr
122 nic acetylcholine receptor was increased and acetylcholinesterase activity was reduced versus control
123 cetylcholine type 2 receptor) receptors, and acetylcholinesterase activity were evaluated in RV (n=11
124 ing of the sacral cord reveals expression of acetylcholinesterase activity, ability to synthesize ace
125 using ultra-centrifugation, and analyzed for acetylcholinesterase activity, total proteins, drug conc
126 lcholine, and paraoxon-induced inhibition of acetylcholinesterase activity.
127 minimal in the shell in part due to elevated acetylcholinesterase activity.
128                       One clue could be that acetylcholinesterase, also present in amyloid plaques, i
129  aimed to evaluate anti-cholinesterase (anti-acetylcholinesterase and -butylcholinesterase), anti-dia
130 sts of alpha-glucosidase, pancreatic lipase, acetylcholinesterase and 15-lipoxygenase were performed.
131 sting, and [(11)C]methylpiperidyl propionate acetylcholinesterase and [(11)C]dihydrotetrabenazine (DT
132 ased segmentation, and focal misalignment of acetylcholinesterase and AChRs.
133 cally used cholinomimetics that both inhibit acetylcholinesterase and also interact directly with and
134                                              Acetylcholinesterase and butyrylcholinesterase accumulat
135 These hybrids are potent inhibitors of human acetylcholinesterase and butyrylcholinesterase in vitro
136 zed and evaluated for binding potency toward acetylcholinesterase and butyrylcholinesterase using enz
137  biological significance (alpha-glucosidase, acetylcholinesterase and butyrylcholinesterase) and free
138 emon juice and chokeberry controls inhibited acetylcholinesterase and butyrylcholinesterase, and this
139 classification of carbon 11-labeled [11C]PMP acetylcholinesterase and caudate nucleus [11C]DTBZ monoa
140 e hypothesis that time-of-day differences in acetylcholinesterase and choline acetyltransferase expre
141 s produced by the enzymatic reaction between acetylcholinesterase and hypoxanthine oxidized antioxida
142 ibitors, with high selectivity against human acetylcholinesterase and low to no toxicity in human cel
143 ta, that is a potent reversible inhibitor of acetylcholinesterase and NMDA receptors, could mitigate
144 iber stained preparations, supplemented with acetylcholinesterase and parvalbumin immunohistochemistr
145 rylated state, which allowed comparison with acetylcholinesterase and rationalization of its ability
146 tion of target site resistance genes such as acetylcholinesterase and the GABA receptor.
147 ferase-positive neurons, as well as, reduced acetylcholinesterase and vesicular acetylcholine transpo
148 s very similar to the primary target of OPs (acetylcholinesterase) and a unique N-terminal alpha-heli
149 1(R) allele expressing the insensitive G119S acetylcholinesterase, and a resistant allele of an unkno
150 r enzymes: alpha-glucosidase, alpha-amylase, acetylcholinesterase, and butyrylcholinesterase.
151 le, ascorbic acid content, antioxidant, anti-acetylcholinesterase, anti-inflammatory and cytotoxic ac
152 nt pathogens, a radical scavenging assay, an acetylcholinesterase assay as well as in situ and ex sit
153 orm capabilities by an in-depth study of the acetylcholinesterase assay, including kinetic parameter
154  method of fabrication of a highly sensitive acetylcholinesterase biosensor and its application to de
155                           A highly sensitive acetylcholinesterase biosensor was developed for detecti
156 ed acetylcholinesterase using the reversible acetylcholinesterase blocker donepezil.
157 ment, [(11)C]methyl-4-piperidinyl propionate acetylcholinesterase brain positron emission tomography
158 t potent inhibitory activities against human acetylcholinesterase, butyrylcholinesterase, and BACE-1,
159 rmeability and multiple activities in vitro (acetylcholinesterase, butyrylcholinesterase, beta-site a
160 reened for their inhibitory activity against acetylcholinesterase, butyrylcholinesterase, lipoxygenas
161 ybdenum assay) and enzyme-inhibitory assays (acetylcholinesterase, butyrylcholinesterase, tyrosinase,
162 nd flavonoid compounds were screened against acetylcholinesterase, butyrylcholinesterase, urease, and
163                       Moderate inhibition of acetylcholinesterase by extracts of all investigated Ros
164 ilarly to previously described inhibition of acetylcholinesterase by rivastigmine and other carbamate
165  revealed when tissue was stained for SMI32, acetylcholinesterase, calbindin, or calretinin.
166 m sections stained for Nissl bodies, myelin, acetylcholinesterase, calbindin, or cytochrome oxidase,
167 solutions of acetic acid as a route to sense acetylcholinesterase-catalyzed hydrolysis of acetylcholi
168                                 They inhibit acetylcholinesterase causing cholinergic crises that lea
169 ion for NADPH diaphorase-expressing, but not acetylcholinesterase-, choline acetyltransferase-, or tr
170 cose oxidase-catalyzed oxidation of glucose, acetylcholinesterase/choline oxidase-mediated hydrolysis
171 protein or its peptide resulted in increased acetylcholinesterase concentration and activity in the A
172 e ColQ deficient mouse, a model of end-plate acetylcholinesterase deficiency.
173 d the utility of (11)C-donepezil for imaging acetylcholinesterase densities in peripheral organs, inc
174  (11)C-donepezil PET is suitable for imaging acetylcholinesterase densities in peripheral organs.
175 donepezil was recently validated for imaging acetylcholinesterase density in the brain and peripheral
176 on and acetylcholine receptor clustering and acetylcholinesterase dispersion seen in the Col13a1-/- m
177 , generated against Electrophorus electricus acetylcholinesterase (EeAChE), inhibits EeAChE and BfACh
178 noencapsulated lutein in the activity of the acetylcholinesterase enzyme.
179 th time-dependent changes in basal forebrain acetylcholinesterase expression.
180  Currently, the four major nerve targets are acetylcholinesterase for organophosphates and methylcarb
181                                          The acetylcholinesterase found in the venom of Bungarus fasc
182           The subsequent enhanced release of acetylcholinesterase from the extant cells could reflect
183      We compared biological functions of two acetylcholinesterase genes (TcAce1 and TcAce2) in Tribol
184 st promising hybrids, the mechanism of human acetylcholinesterase (hAChE) inhibition as well as their
185 lkylamine reactivators of phosphylated human acetylcholinesterase (hAChE) intended to catalyze the hy
186                                        Human acetylcholinesterase (hAChE), an enzyme mediating synapt
187 sarin, VX, and paraoxon) conjugates of human acetylcholinesterase (hAChE).
188 se two scenarios: the synaptic form of human acetylcholinesterase (hAChE-S) associates with plaques i
189                                              Acetylcholinesterase histology has been used for many ye
190 were evaluated using confocal microscopy and acetylcholinesterase histology.
191 tion volume ratio) and thalamic and cortical acetylcholinesterase hydrolysis rate per minute (k3), re
192                        Firstly, an effective acetylcholinesterase immobilized electrode was developed
193  cells was monitored by measuring release of acetylcholinesterase in cell perfusates using the Ellman
194          Feeding flies choline or inhibiting acetylcholinesterase in Pn enhances memory, an effect bl
195 lloenzymes that hydrolyze a variety of toxic acetylcholinesterase-inhibiting organophosphorus compoun
196 ntly (p < 0.05) higher alpha-glucosidase and acetylcholinesterase inhibition activities were observed
197 for free fraction, and alpha-glucosidase and acetylcholinesterase inhibition for whole fraction.
198  of dichlorvos based on polydiacethylene and acetylcholinesterase inhibition is developed.
199 teine, two novel reversal drugs that have no acetylcholinesterase inhibition properties.
200 is study investigates, whether pharmacologic acetylcholinesterase inhibition with neostigmine diminis
201 ulating the parasympathetic activity through acetylcholinesterase inhibition, in experimental pulmona
202 s behind this toxidrome in humans, including acetylcholinesterase inhibition, N-methyl-D-aspartate re
203 dynamics to determine ACh's effects, via the acetylcholinesterase inhibitor (AChEI) donepezil, on the
204 naptic morphology and weak resistance to the acetylcholinesterase inhibitor aldicarb, they are signif
205 muscular junction during lethargus using the acetylcholinesterase inhibitor aldicarb.
206 naling mutants and transgenic animals to the acetylcholinesterase inhibitor aldicarb.
207 y of sacral VF neurons in the presence of an acetylcholinesterase inhibitor can be partially ascribed
208 ve M(1) PAM VU0453595 in comparison with the acetylcholinesterase inhibitor donepezil, M(1)/M(4) agon
209 demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug into brain-penetrabl
210 ments of the neonatal rat spinal cord to the acetylcholinesterase inhibitor edrophonium (EDR).
211  consisting of the epidural injection of the acetylcholinesterase inhibitor neostigmine.
212                                              Acetylcholinesterase inhibitor reversal can cause respir
213 eliorating this cholinergic deficit with the acetylcholinesterase inhibitor rivastigmine would reduce
214      For Alzheimer disease, this includes an acetylcholinesterase inhibitor such as donepezil for mil
215                            Galantamine is an acetylcholinesterase inhibitor that also acts as a posit
216                            Neostigmine is an acetylcholinesterase inhibitor that ameliorates the effe
217  and functional network enhancements with an acetylcholinesterase inhibitor treatment (donepezil) whe
218  are more likely to cognitively improve with acetylcholinesterase inhibitor treatment.
219 nd no evidence that age, disease severity or acetylcholinesterase inhibitor use influenced rate of de
220  (defined by hospital discharge diagnosis or acetylcholinesterase inhibitor use).
221 ce for influence by age, disease severity or acetylcholinesterase inhibitor use.
222 observed in 6 of 66 patients who received an acetylcholinesterase inhibitor, 65 of 69 patients who re
223 utants also exhibited hypersensitivity to an acetylcholinesterase inhibitor, aldicarb, uncovering def
224 thout an aid, had no previous exposure to an acetylcholinesterase inhibitor, and did not have dementi
225 milar in normal and lesioned animals and the acetylcholinesterase inhibitor, donepezil (1 mg/kg), pro
226                                Donepezil, an acetylcholinesterase inhibitor, is an approved drug for
227 ic activation by systemic application of the acetylcholinesterase inhibitor, physostigmine, resulted
228 treatment with donepezil, a centrally active acetylcholinesterase inhibitor, prevented and reversed o
229 macological intervention using donepezil, an acetylcholinesterase inhibitor.
230     With the aim of reducing side effects of acetylcholinesterase inhibitors (AChEIs) during symptoma
231 meta-analysis investigating the influence of acetylcholinesterase inhibitors (AChEIs) therapy on nutr
232 oestrogen replacement therapy (Level A2) and acetylcholinesterase inhibitors (Level B).
233 re also limited by common adverse effects of acetylcholinesterase inhibitors and limited availability
234                                              Acetylcholinesterase inhibitors and memantine hydrochlor
235 s to examine the safety of NMB reversal with acetylcholinesterase inhibitors and muscarinic anticholi
236 se Research Centre who subsequently received acetylcholinesterase inhibitors and underwent magnetic r
237                                              Acetylcholinesterase inhibitors are commonly used to tre
238  +/- 6.7 years); 71% of the patients were on acetylcholinesterase inhibitors at baseline; mean Mini-M
239 tors; however, in some cases the efficacy of acetylcholinesterase inhibitors diminishes over time.
240                                              Acetylcholinesterase inhibitors have also been shown to
241 ion tomography predict treatment response to acetylcholinesterase inhibitors in patients with dementi
242 AD, and enhancing cholinergic signaling with acetylcholinesterase inhibitors is currently the primary
243                              The response to acetylcholinesterase inhibitors is often disappointing.
244 racting the detrimental effects of long-term acetylcholinesterase inhibitors on the postsynaptic neur
245                               Treatment with acetylcholinesterase inhibitors resulted in worsened con
246 o acquired myasthenia gravis, treatment with acetylcholinesterase inhibitors should be avoided in DOK
247 e specific examples of the therapeutics from acetylcholinesterase inhibitors to recent anti-Abeta imm
248                                       Use of acetylcholinesterase inhibitors was prohibited.
249 tor agonists) and organophosphate miticides (acetylcholinesterase inhibitors).
250                    The beneficial effects of acetylcholinesterase inhibitors, however, are typically
251 nvestigating pharmacological therapies using acetylcholinesterase inhibitors, such as pyridostigmine
252 oup and includes symptomatic treatment using acetylcholinesterase inhibitors, thymectomy and immunoth
253 of age, disease severity and baseline use of acetylcholinesterase inhibitors.
254 lcholine receptor deficiency respond well to acetylcholinesterase inhibitors; however, in some cases
255           Ex vivo determination of the brain acetylcholinesterase inhibitory activity of these compou
256 nds that exert antioxidative, antimicrobial, acetylcholinesterase inhibitory and estrogenic activitie
257 aying both nanomolar dual-binding site (DBS) acetylcholinesterase inhibitory effects and partial 5-HT
258           The hydrolysis of acetylcholine by acetylcholinesterase into choline was monitored in real-
259                                              Acetylcholinesterase is an enzyme that is intimately ass
260                      The overall activity of acetylcholinesterase is found to decline in AD, whereas
261 ncoding the acetylcholine-hydrolyzing enzyme acetylcholinesterase is known to undergo long-lasting tr
262 pite the modest ability to inhibit rat brain acetylcholinesterase, it protects neuronal SH-SY5Y cells
263  5-(11)C-methoxy-donepezil, a noncompetitive acetylcholinesterase ligand, was previously validated fo
264                  Functionally, iHPs generate acetylcholinesterase(+) megakaryocytes and phagocytic my
265 he graft-host junction were subjected to the acetylcholinesterase method for the demonstration of cor
266  only in the shell, where higher activity of acetylcholinesterase minimizes nAChR desensitization and
267              The response characteristics of acetylcholinesterase-modified AlGaN/GaN solution-gate fi
268 f fluorescent probes-one to detect the total acetylcholinesterase on erythrocytes (RBC-AChE) and the
269 untermeasures such as antidotes reactivating acetylcholinesterase or scavenging the parent OP.
270 rived butyrylcholinesterase and erythrocytic acetylcholinesterase) or nonexisting (synaptic acetylcho
271 he largest peptidic inhibitors targeting the acetylcholinesterase peripheral site.
272 sferase-positive cells in this region and of acetylcholinesterase-positive fibers throughout the audi
273 toneuron volume and a near-normal density of acetylcholinesterase-positive process arborization, whic
274                                         Past acetylcholinesterase positron emission tomography (PET)
275  2 and (11)C-methylpiperidin-4-yl propionate acetylcholinesterase positron emission tomography and th
276  mouse model overexpressing a miR refractory acetylcholinesterase-R splice variant showed a parallel
277 s to assess the bioactivity of a fragment of acetylcholinesterase responsible for its non-enzymatic f
278                       This exposure inhibits acetylcholinesterase resulting in increased acetylcholin
279 LQ (collagen-like tail subunit of asymmetric acetylcholinesterase; rs7609897-T: P=1.5 x 10(-10), OR=0
280 l candidate inhibitors from a screen against acetylcholinesterase show detectable activity; beyond th
281 9 cells transfected with either p53 siRNA or acetylcholinesterase siRNA.
282                           To explore a novel acetylcholinesterase species, ascertain the molecular ba
283 ious genotypes, myenteric plexus presence by acetylcholinesterase staining and embryonic day 12.5 (E1
284 fAChE forms the canonical dimer found in all acetylcholinesterase structures.
285 osedimented with eHAV but not membrane-bound acetylcholinesterase, suggesting that eHAV, and not vira
286 then evoke a subsequent, enhanced release in acetylcholinesterase that could only be derived from the
287 croinjection of neostigmine, an inhibitor of acetylcholinesterase, that evoked rapid increases in ace
288 known naturally occurring hydrolytic enzyme, acetylcholinesterase, the catalytic activity of which ap
289      Donepezil is a high-affinity ligand for acetylcholinesterase-the enzyme that catabolizes acetylc
290  of beta-amyloid with a peptide derived from acetylcholinesterase: the similarity in action suggests
291 choline which is enzymatically hydrolyzed by acetylcholinesterase to myristic acid and choline to pre
292 antimicrobials, estrogen-like activators and acetylcholinesterase/tyrosinase inhibitors.
293 e related to the activity of the immobilized acetylcholinesterase using the reversible acetylcholines
294 re recently, a gene purportedly encoding for acetylcholinesterase was cloned from maize.
295                                              Acetylcholinesterase was electro-immobilized into a thic
296               We show proof-of-concept where acetylcholinesterase was immobilized on an organosiloxan
297 fos-induced inhibition of its target enzyme (acetylcholinesterase) was only magnified by the heat spi
298 hermal properties.The two molecular forms of acetylcholinesterase were purified from the brain of T.
299 obiase, catalase, xenobiotic metabolism, and acetylcholinesterase) were measured in the adults.
300   Physostigmine is a well known inhibitor of acetylcholinesterase, which can also activate, potentiat

 
Page Top